Anti-hIL17A-hIgG1
-
Cat.code:
hil17a-mab1
- Documents
ABOUT
Anti-human IL-17A - Secukinumab biosimilar - CAS #1229022-83-6
Anti-hIL-17A-hIgG1 is a biosimilar antibody of Secukinumab, a human interleukin-17A (IL-17A) antibody that specifically blocks IL-17A signaling. This monoclonal antibody (mAb) is FDA-approved for treating moderate-to-severe plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.
Anti-hIL-17A-hIgG1 comprises the variable region of Secukinumab and the IgG1 constant region of Secukinumab, mediating high effector functions.
This antibody can be used together with HEK-Blue™ IL-17 cells for screening and neutralization assays to block IL-17A signaling induced by recombinant human IL-17A (see figure).
Key features
- Each lot is functionally tested and validated.
- The complete sequence of the antibody construct has been verified.
- The absence of endotoxins is determined by the EndotoxDetect™ assay.
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
IL-17A
Human
Sodium phosphate buffer with glycine, saccharose, and stabilizing agents
Negative (tested using EndotoxDetect™ assay)
Neutralization assay, ELISA
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hIL17A-hIgG1
-
Cat code:hil17a-mab1
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20 °C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Secukinumab background
Secukinumab (AIN457), a fully human anti-hIL-17A-hIgG1 mAb, was designed to selectively target the human interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in Th17 immunity as well as in the pathogenesis of autoimmune diseases [1]. IL-17A, also known as CTLA‑8, is able to induce chemokine production, neutrophil influx, and the production of antibacterial peptides [2].
By binding IL-17A, Secukinumab prevents its interaction with the IL-17 receptor complex (IL-17RA/RC), thereby inhibiting downstream inflammatory signaling and cytokine production [2-3]. Secukinumab has demonstrated strong clinical efficacy in improving skin lesions and joint symptoms. In 2015, this first-in-class anti-IL-17A mAb was approved by the FDA for the treatment of moderate-to-severe plaque psoriasis, leading to the complete clearance of psoriatic plaques [3]. One year later, Secukinumab was also approved for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) [3]. Surprisingly, trials of Secukinumab in Crohn’s disease were terminated early due to worsening of the disease in the treatment group [2-3]. These findings agree with IL-17's supportive role in skin wound healing [2].
References:
1. Monin L. & Gaffen S.L., 2018. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb Perspect Biol. 10(4).
2. Huangfu L, Li R, Huang Y, Wang S, 2023. The IL-17 family in diseases: from bench to bedside. Signal Transduct Target Ther.11;8(1):402.
3. Amatya N, Garg AV, Gaffen SL, 2017. IL-17 Signaling: The Yin and the Yang. Trends Immunol. 38(5):310-322
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
